MoonLake Immunotherapeutics

MLTX

$1.01B

Small Cap

NASDAQBiotechnology🇺🇸North America100 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 27, 2026

14w

Drug Pipeline

Drug Name	Phase	Indication	Designations
Sonelokimab	Phase 3	Hidradenitis Suppurativa	-
Placebo	Phase 3	Arthritis, Psoriatic	-
Risankizumab	Phase 3	Arthritis, Psoriatic	-
Adalimumab	Phase 2	Arthritis, Psoriatic	-
Sonelokimab (M1095)	Phase 2	Hidradenitis Suppurativa	-

Catalyst Timeline

1 upcoming, 0 past

⭐Phase 3Next

Mar 27, 2026Sonelokimab

Primary completion for Sonelokimab trial (NCT06768671) in Hidradenitis Suppurativa

Regulatory Approvals

MLTX News